Based on the data of JAVELIN Renal 100, JAVELIN Renal 101, a randomized, multicenter, phase III study (NCT02684006) comparing avelumab (fully human IgG1 anti–PD-L1 antibody) plus axitinib vs. sunitinib in treatment-naive RCC patients has been initiated—the primary objective is to demonstrate the superiority of avelumab in combination with axitinib compared to sunitinib in PFS (Table 3). Here, CD274 is linked to renal cell adenocarcinoma.